(Hypertension. 2000;35:108.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From the University of Georgia Colleges of Pharmacy (P.V.G.K., M.R.U., A.W.M.) and Veterinary Medicine (M.H.), Medical College of Georgia School of Medicine (M.R.U., A.W.M.), and Augusta VA Medical Center (P.V.G.K., M.R.U., A.W.M.), Augusta, Ga.
Correspondence to Dr Allison W. Miller, Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157. E-mail amiller{at}wfubmc.edu
AbstractThis study assessed the effect of metformin treatment on insulin, mean arterial pressure (MAP), and endothelial function in insulin-resistant (IR) rats. In addition, we assessed the direct effect of metformin in vitro. Sprague-Dawley rats were randomized to control (n=28) or IR (n=28) groups. Rats were further randomized to receive metformin (300 mg/kg) or placebo for 2 weeks. MAP and insulin were measured. Subsequently, a third-order branch of the superior mesenteric artery was isolated, and endothelial function was assessed. Specifically, dose-response experiments of acetylcholine (ACh) with or without N-nitro-L-arginine (LNNA) were performed. For in vitro experiments, mesenteric arteries were removed from untreated control and IR rats and treated with metformin (100 µmol/L) before ACh±LNNA. MAP and insulin levels were improved in IR-metformin compared with IR-placebo rats. Maximal relaxation (Emax) to ACh was enhanced in IR-metformin (92±2%) compared with IR-placebo rats (44±4%) (P<0.05). Relaxation in response to ACh+LNNA was greater in IR-metformin (33±4%) than in IR-placebo rats (12±4%) but remained depressed compared with control rats (Emax=68±5%). The control group was not affected by metformin. In vitro treatment of arteries with metformin in response to ACh produced results similar to those in the experiments with metformin-treated rats. Although metformin improves metabolic abnormality in IR rats, this action does not appear to mediate its effect on vascular function. Both in vivo and in vitro metformin improved ACh-induced relaxation in IR rats to control levels, apparently through nitric oxidedependent relaxation. These data suggest that metformin improves vascular function through a direct mechanism rather than by improving metabolic abnormalities.
Key Words: insulin resistance relaxation metformin nitric oxide blood pressure
This article has been cited by other articles:
![]() |
H. Sasaki, H. Asanuma, M. Fujita, H. Takahama, M. Wakeno, S. Ito, A. Ogai, M. Asakura, J. Kim, T. Minamino, et al. Metformin Prevents Progression of Heart Failure in Dogs: Role of AMP-Activated Protein Kinase Circulation, May 19, 2009; 119(19): 2568 - 2577. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsumoto, E. Noguchi, K. Ishida, T. Kobayashi, N. Yamada, and K. Kamata Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1165 - H1176. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sydow, C. E. Mondon, J. Schrader, H. Konishi, and J. P. Cooke Dimethylarginine Dimethylaminohydrolase Overexpression Enhances Insulin Sensitivity Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 692 - 697. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xie, Y. Dong, R. Scholz, D. Neumann, and M.-H. Zou Phosphorylation of LKB1 at Serine 428 by Protein Kinase C-{zeta} Is Required for Metformin-Enhanced Activation of the AMP-Activated Protein Kinase in Endothelial Cells Circulation, February 19, 2008; 117(7): 952 - 962. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-J. Lee, D. Feliers, M. M. Mariappan, K. Sataranatarajan, L. Mahimainathan, N. Musi, M. Foretz, B. Viollet, J. M. Weinberg, G. G. Choudhury, et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy Am J Physiol Renal Physiol, February 1, 2007; 292(2): F617 - F627. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. K. de Aguiar, L. R. Bahia, N. Villela, C. Laflor, F. Sicuro, N. Wiernsperger, D. Bottino, and E. Bouskela Metformin Improves Endothelial Vascular Reactivity in First-Degree Relatives of Type 2 Diabetic Patients With Metabolic Syndrome and Normal Glucose Tolerance Diabetes Care, May 1, 2006; 29(5): 1083 - 1089. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Davis, Z. Xie, B. Viollet, and M.-H. Zou Activation of the AMP-Activated Kinase by Antidiabetes Drug Metformin Stimulates Nitric Oxide Synthesis In Vivo by Promoting the Association of Heat Shock Protein 90 and Endothelial Nitric Oxide Synthase Diabetes, February 1, 2006; 55(2): 496 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D'Angelo, A. A. Elmarakby, D. M. Pollock, and D. W. Stepp Fructose Feeding Increases Insulin Resistance but Not Blood Pressure in Sprague-Dawley Rats Hypertension, October 1, 2005; 46(4): 806 - 811. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sydow, C. E Mondon, and J. P Cooke Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA Vascular Medicine, July 1, 2005; 10(1_suppl): S35 - S43. [Abstract] [PDF] |
||||
![]() |
K. Sydow, C. E Mondon, and J. P Cooke Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA Vascular Medicine, May 1, 2005; 10(2_suppl): S35 - S43. [Abstract] [PDF] |
||||
![]() |
A. Gallo, G. Ceolotto, P. Pinton, E. Iori, E. Murphy, G. A. Rutter, R. Rizzuto, A. Semplicini, and A. Avogaro Metformin Prevents Glucose-Induced Protein Kinase C-{beta}2 Activation in Human Umbilical Vein Endothelial Cells Through an Antioxidant Mechanism Diabetes, April 1, 2005; 54(4): 1123 - 1131. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Zou, S. S. Kirkpatrick, B. J. Davis, J. S. Nelson, W. G. Wiles IV, U. Schlattner, D. Neumann, M. Brownlee, M. B. Freeman, and M. H. Goldman Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drug Metformin in Vivo: ROLE OF MITOCHONDRIAL REACTIVE NITROGEN SPECIES J. Biol. Chem., October 15, 2004; 279(42): 43940 - 43951. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-S. Wang, H. Kusuhara, Y. Kato, J. W. Jonker, A. H. Schinkel, and Y. Sugiyama Involvement of Organic Cation Transporter 1 in the Lactic Acidosis Caused by Metformin Mol. Pharmacol., April 1, 2003; 63(4): 844 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-S. Wang, J. W. Jonker, Y. Kato, H. Kusuhara, A. H. Schinkel, and Y. Sugiyama Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 510 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Severino, P. Brizzi, A. Solinas, G. Secchi, M. Maioli, and G. Tonolo Low-dose dexamethasone in the rat: a model to study insulin resistance Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E367 - E373. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kirpichnikov, S. I. McFarlane, and J. R. Sowers Metformin: An Update Ann Intern Med, July 2, 2002; 137(1): 25 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Mather, S. Verma, and T. J. Anderson Improved endothelial function with metformin in type 2 diabetes mellitus J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1344 - 1350. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |